Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354036 | 0.94 | INPPL1 (0.43) | INPPL1ADRB2ALDH1A1 | |
| SCHEMBL12337534 | 0.86 | CYP3A4 (0.45) | CYP3A4MEN1GAAKMT2A | |
| SCHEMBL12337535 | 0.86 | CYP3A4 (0.40) | CYP3A4GAAL3MBTL1 | |
| SCHEMBL2354041 | 0.85 | INPPL1 (0.49) | INPPL1ADRB2ALDH1A1 | |
| SCHEMBL2463713 | 0.84 | MAOB (0.43) | ADRB2TSHR | |
| SCHEMBL2351410 | 0.79 | INPPL1 (0.46) | INPPL1ADRB2TSHRMEN1ALDH1A1 | |
| SCHEMBL12313531 | 0.76 | PKM (0.48) | ADRB2TSHR | |
| SCHEMBL12313590 | 0.74 | INPPL1 (0.55) | INPPL1ALDH1A1L3MBTL1 | |
| SCHEMBL14930188 | 0.73 | LTA4H (0.52) | ADRB2TSHRMEN1NPC1ALDH1A1 | |
| SCHEMBL12337537 | 0.73 | INPPL1 (0.51) | INPPL1ALDH1A1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | CYP3A4 37/4885INPPL1 1753/4885ADRB2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.